Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
0(0%)
Results Posted
120%(12 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
7
58%
Ph phase_3
5
42%

Phase Distribution

7

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
7(58.3%)
Phase 3Large-scale testing
5(41.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Terminated(2)

Detailed Status

Completed10
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (58.3%)
Phase 35 (41.7%)

Trials by Status

completed1083%
terminated217%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04165824
completedphase_3

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

NCT05568615
completedphase_3

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04577404
terminatedphase_3

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04569084
completedphase_1

Study of Oral Edaravone in Healthy Adult Males

NCT04481750
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04165824Phase 3

Safety Study of Oral Edaravone Administered in Subjects With ALS

Completed
NCT05568615Phase 3

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

Completed
NCT04577404Phase 3

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT04569084Phase 3

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Terminated
NCT04481750Phase 1

Study of Oral Edaravone in Healthy Adult Males

Completed
NCT04254913Phase 1

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Completed
NCT04776135Phase 1

Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube

Completed
NCT05342597Phase 1

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Completed
NCT04481789Phase 1

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Completed
NCT04176224Phase 1

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

Completed
NCT04493281Phase 1

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Completed
NCT05151471Phase 3

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12